• Acetoacetic Acid Sodium Salt: Evidence and Scope

  2026-10-18

  The APExBIO catalog identifies acetoacetic acid sodium salt as sodium 3-oxobutanoate, a ketone-body-related metabolite associated with hepatic fatty acid catabolism and diabetes metabolic imbalance. Its documented mechanism is limited to the supplier’s description of conversion to acetoacetic acid and its metabolic context. No identity-matched research paper, outcome dataset, assay validation, or independent performance comparison is available in the supplied evidence.

• Acetoacetic Acid Sodium Salt: Evidence and Scope

  2026-10-17

  Acetoacetic acid sodium salt, also identified as sodium 3-oxobutanoate, is described by APExBIO as a water-soluble sodium form of acetoacetate, a ketone body associated with fatty acid catabolism and energy metabolism. The available evidence is limited to product documentation: it supports chemical identity, stated quality attributes, and a broad mechanistic context, but does not establish biological efficacy, model-specific performance, or clinical utility.

• Acetoacetic Acid Sodium Salt: Evidence and Scope

  2026-10-16

  Acetoacetic acid sodium salt, identified by APExBIO as sodium 3-oxobutanoate, is documented as a ketone-body-related metabolite relevant to energy metabolism research and diabetes metabolic imbalance. The available material supports chemical identity, supplier-reported characterization, and a conceptual relationship to hepatic fatty acid catabolism. It does not provide an identity-matched study, assay-validation data, clinical evidence, comparative performance results, or product-specific biological outcomes.

• Sodium Chloride: Identity, Mechanism, and Evidence Scope

  2026-10-16

  APExBIO B7288 is documented as sodium chloride (NaCl), an inorganic salt with CAS 7647-14-5, a listed molecular weight of 58.44, and stated 98% purity. The product description supports a conceptual role in aqueous ionic-strength regulation, osmotic balance, buffer preparation, and cell culture media, but no identity-matched research paper or product-specific outcome data are available. Accordingly, the evidence establishes documented identity and intended scientific scope, not application performance, sterility, or comparative efficacy.

• Acetoacetic Acid Sodium Salt: Evidence and Scope

  2026-10-15

  The APExBIO product page identifies Acetoacetic acid sodium salt, or sodium 3-oxobutanoate, as a sodium-form ketone body associated with fatty acid catabolism and diabetes-related metabolic imbalance. It provides catalog identity, reported purity, and physicochemical properties, but the available material contains no identity-matched research study establishing biological performance, causal mechanism, or clinical applicability.

• Acetoacetic Acid Sodium Salt: Evidence and Scope

  2026-10-15

  Acetoacetic acid sodium salt, or sodium 3-oxobutanoate, is documented by APExBIO as a ketone-body-related metabolite for energy metabolism and diabetes research contexts. The available product information supports identity, selected physicochemical properties, and a conceptual relationship between acetoacetate, fatty acid catabolism, and metabolic imbalance. It does not provide an identity-matched study, efficacy data, assay validation, diagnostic thresholds, or evidence that this commercial material reproduces a disease state.

• 5-Methoxy-UTP: What the Record Supports

  2026-10-14

  The available evidence supports only a catalog-level identification of 5-Methoxy-UTP, listed by APExBIO as SKU B8061. No identity-matched study, product-specific mechanism, measurement principle, performance result, or biological outcome is documented, so interpretation should remain limited to nominal chemical identity and supplier provenance.

• Fyn–STAT3 Neurodegeneration: Evidence and Limits

  2026-10-14

  A 2024 zebrafish study links constitutively active Fyn signaling to dopaminergic neuron loss, mitochondrial abnormalities and microglial inflammation, identifying STAT3 as a downstream contributor that acts with NF-κB. The findings provide a mechanistic framework for neurodegeneration research, but their applicability is bounded by the larval zebrafish model, engineered Fyn activation and pathway-focused perturbations. EZ Cap™ Cas9 mRNA (5-moUTP) is conceptually relevant to CRISPR-Cas9 genome editing and functional gene studies, but the supplied evidence does not show that the product was used in this study or that it has disease-model or therapeutic efficacy.

• What the 2026 Review Says About Drying mRNA-LNPs

  2026-10-13

  Zhen and colleagues review how drying technologies may improve the storage stability of mRNA and other nucleic-acid lipid nanoparticles (NA-LNPs). The evidence supports drying as a promising formulation strategy, but the review also highlights substantial structure-, formulation-, and process-dependent uncertainty.

• D-Mannitol: Identity and Evidence Scope

  2026-10-13

  D-Mannitol is a supplier-listed polyol reagent with a stated role as an osmotic diuretic agent and conceptual relevance to osmotic regulation research, renal function studies, and diuretic mechanism investigation. No matched paper or product-specific experimental evidence was provided, so efficacy, mechanism, comparisons, and disease-specific applicability remain unverified.

• GPR35–KLF5 and Intestinal Repair

  2026-10-12

  A 2026 Cell Death & Disease study proposes that GPR35 connects tryptophan metabolism to KLF5-dependent intestinal epithelial repair. The findings offer a mechanistic framework for ulcerative colitis research, while the supplied record leaves important questions about model scope, quantitative evidence, and relevance to human disease.

• What the CYR61–Migrasome Study Shows—and Misses

  2026-10-12

  The supplied 2025 study supports a model in which CYR61-associated migrasomes may help restore migration and osteogenic behavior in irradiated BMSCs, but its findings do not establish clinical efficacy or compare protein-preservation reagents. Product claims for an MS-compatible Protease Inhibitor Cocktail should therefore remain separate from the study’s biological conclusions.

• PRINT: RNA-Mediated Safe-Harbor Insertion

  2026-10-10

  A Nature Biotechnology study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to direct transgene synthesis into a multicopy human safe-harbor locus. The reported results show substantial insertion of kilobase-scale transgenes in cultured human primary cells, while also defining important limitations around template recognition, junction verification, and transferability beyond the tested model.

• Entecavir and HBV Resistance: Meta-Analysis Findings

  2026-10-09

  Lumley and colleagues provide the first systematic review and meta-analysis to pool sequence-defined hepatitis B virus resistance estimates for entecavir and tenofovir over time. The analysis found low cumulative resistance to entecavir in treatment-naive populations, substantially higher resistance among nucleos(t)ide-experienced participants, and no pooled tenofovir resistance signal—although important evidence gaps limit interpretation.

• Sodium Chloride B7288: Product Overview

  2026-10-09

  Sodium chloride B7288 is a supplier-listed inorganic salt with the identity NaCl, molecular weight 58.44, CAS 7647-14-5, and stated purity of 98%. No matched paper evidence is available for this specific product.

7957 records 1/531 page Next 12345 下5页 Last page